Rituximab in kidney disease and transplant

Kajal Chauhan | Anita A. Mehta

1 Medical Services, Torrent Pharmaceuticals, Ahmedabad, India
2 Department of Pharmacology, L. M. College of Pharmacy, Ahmedabad, Gujarat, India

Correspondence
Anita A. Mehta, Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmedabad 380009, India. Email: dranitalmcp@gmail.com

Abstract
Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B-cells. It depletes the level of mature B-cells by various mechanisms such as mediation of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and B-cell apoptosis. Rituximab is a USFDA approved drug for clinical use in non-Hodgkin’s B-cell lymphoma (NHL), rheumatoid arthritis, chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis and pemphigus vulgaris. It is also known for its “off label” use in renal disease and renal transplant worldwide. However, the exact mechanisms by which it exerts its effect in the aforementioned condition remain unclear but may be related to its long-term effects on plasma cell development and the impact on B-cell modulation of T-cell responses. This review discusses the current use of rituximab in renal disease and renal transplantation, and its potential role in novel therapeutic protocols.

KEYWORDS
renal diseases, renal transplant, rituximab

1 | INTRODUCTION

Rituximab is a chimeric murine/human monoclonal IgG1 kappa monoclonal antibody that binds to the CD20 antigen present on the cell surface. It is a product consisting of approximately 20% mouse and 80% human protein and was the first monoclonal antibody to be approved for clinical use in the therapy of cancer patients suffering from lymphoma. It is approved for use against indolent B-cell non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) in patients with an incomplete response or intolerance to tumor necrosis inhibitors (TNFi), granulomatosis with polyangiitis and microscopic polyangiitis. Recently rituximab has been approved by the USFDA for pemphigus vulgaris.

CD20, an activated-glycosylated phosphoprotein, is an antigen expressed on the surface of B-cells in pre-B-cell and mature phases. Rituximab depletes mature B-cells and pre-B-cells through memory B-cell stages only if this trans-membrane antigenic protein is present. It doesn’t deplete stem cells, pro-B-cells, terminally differentiated plasma cells, and plasmablasts because these cells do not express CD20 on their surfaces. Rituximab depletes B-cells by various mechanisms, including mediation of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and B-cell apoptosis. It has been shown to be efficacious in clinical trials of patients with RA and hematological malignancies, with a reasonable safety profile and a small risk of serious infectious events. Treatment effects were stable over time and repeated courses. Other opportunistic infections were rare with the treatment.

Antibody production is a characteristic and pathological marker for number of systemic diseases. It may affect the kidneys and may lead to serious problems in renal transplantation. Rituximab is known for its “off label” use for the treatment of various disorders, but the exact mechanism by which it exerts its effect remains unclear. It is used to treat systemic lupus erythematosus, membranous nephropathy, mixed essential cryoglobulinaemia, focal segmental glomerulosclerosis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and hemolytic uremic syndrome, specifically in cases which are resistant to conventional therapy. In transplantation, it is used in induction/desensitization in refractory-B-cell-associated or antibody-associated rejection. Herein, we review the latest reports on the use...
of rituximab in kidney disease and transplantation. Randomized controlled trials are warranted for several of the indications discussed below, to confirm or refute the benefits reported to date.

2 | SYSTEMIC LUPUS ERYTHEMATOSUS

Lupus nephritis is a major cause of mortality and morbidity in patients with SLE, with renal involvement occurring in up to two-thirds of patients. B-cells are thought to play a crucial role in the pathogenesis of SLE, including the production of autoantibodies, the regulation of T-cell activation, and the production of cytokines involved in the disease; therefore, rituximab would seem a logical therapeutic choice in SLE. Ruth et al reported in a prospectively monitored cohort of 18 patients, who were on steroids prior to the development of lupus nephritis, treated with rituximab induction therapy (two 1 g doses of rituximab, given on days 1 and 15) and mycophenolate mofetil (MMF) maintenance therapy (1 g/d). Seventy-eight per cent of patients achieved a complete response (CR) or partial remission (PR), with a sustained response of 12/18 (67%) at 1 year. Proteinuria significantly decreased from a mean protein:creatinine ratio (PCR) of 325 mg/mmol to 132 mg/mmol at 1 year (P = 0.004). There was a significant increase in serum albumin from a mean of 29.34 g/L at 1 year (P = 0.001). No severe infections were reported. Six patients stopped prednisolone, and 6 patients reduced their maintenance dose.

Borja Gracia-Tello et al reported that early treatment of SLE patients with rituximab was safe and effective, and enabled a reduction in steroid use. Sixteen female patients with SLE were treated at or shortly after diagnosis with rituximab (1 g on days 1 and 14). All patients given rituximab achieved B-cell depletion. The mean number of flares during follow-up was 2.63 in the rituximab group and 4 in the controls (NS, P = 0.14). After treatment with rituximab, mean anti-dsDNA antibody level fell from 1114 to 194 U/mL at 18 months (P = 0.043), mean serum erythrocyte sedimentation rate (ESR) fell by > 70% at 6 months and was maintained during follow-up, and serum complement (C3) level normalised in eight patients. The mean cumulative prednisolone dose at 60 months for the patients who were given rituximab (n = 11) was 4745.67 mg vs 12 553.92 mg for the controls (P = 0.01).

3 | IDIOPATHIC MEMBRANOUS NEPHROPATHY

Membranous nephropathy (MN) remains a leading cause of nephrotic syndrome in adults. In most patients, an underlying etiology for the lesion is unknown and the disorder is termed idiopathic. The M-type phospholipase A2 receptor (PLA2R), a transmembrane protein expressed on glomerular podocytes, has been demonstrated to be the target antigen in most cases of idiopathic MN (IMN). This creates a paradigm whereby circulating autoantibodies to PLA2R form in situ immune complexes at the level of the podocyte, leading to the development of MN. The central mechanistic role for autoantibodies in MN has provided a rationale for B-cell targeted therapy. Remuzzi et al used rituximab successfully in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. Four weekly infusions of rituximab (375 mg/m²) were given. At the end of weeks 4 and 20, urinary protein decreased from a mean (SE) of 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (P < 0.0001). At week 20, albuminuria and albumin fractional clearance decreased by 70% and 65%, and serum albumin increased by 31%. CD20 B lymphocytes also fell below normal ranges up to study end.

Marco et al confirmed that treatment with rituximab (in 13 patients as first-line therapy, in the remaining 25 after conventional immunosuppressive therapy) was remarkably safe and allowed for a large percentage of complete or partial remissions in 38 patients with MN. Patients were given four weekly intravenous infusions of rituximab at a dose of 375 mg/m², and 39.5% (15 patients), 36.8% (14 patients) and 76.3% (29 patients) achieved complete remission, partial remission and the composite endpoint (complete or partial remission), respectively. The 24-h proteinuria level was reduced significantly, while albuminuria increased constantly. Renal function did not significantly change during the observation period. Circulating CD19+ B-cells were reduced significantly from the baseline value to the 24-month value (P < 0.01). Clinical outcomes of IMN patients treated with rituximab are summarized in Table 1.

4 | MIXED ESSENTIAL CRYOGLOBULINEMIA

Mixed cryoglobulinemia is a systemic vasculitis, primarily mediated by immune complexes and is associated with hepatitis C virus (HCV) infection and B-cell lymphoproliferation. Rituximab has the potential to deplete the expanded population of B-cells developing in HCV-associated vasculitis thereby reducing the formation of the cryoglobulin immune complex. In a prospective randomized controlled trial, Sneller et al treated 24 HCV-associated cryoglobulinemic patients with rituximab (375 mg/m² per week for 4 weeks). Eighty-three per cent of patients achieved remission compared with one patient in the control group (8%), a result that met the criterion for stopping the study (P < 0.001). No adverse effect of rituximab on HCV plasma viremia or hepatic transaminase levels was observed.

In a long-term, prospective, randomized controlled trial, De Vita et al reported that rituximab monotherapy represents a very good option for severe cryoglobulinemic vasculitis and can be maintained over the long term in most patients. Fifty-nine patients were randomized to nonrituximab (RTX) or RTX groups (two infusions of 1 g each). Survival of treatment at 12 months, the primary end point, was statistically higher in the RTX group (64.3% vs 35.5%; P < 0.0001), as well as at 3 months (92.9% vs 13.8%; P < 0.0001), 6 months (71.4% vs 35.5%; P < 0.0001), and 24 months (60.7% vs 35.5%; P < 0.0001). The Birmingham Vasculitis Activity Score decreased only after treatment with rituximab (11.9 ± 5.4 vs 1.3 ± 1.6; P < 0.0001).
TABLE 1  Rituximab in idiopathic membranous nephropathy

| Reference         | Study Type                           | Dose of rituximab                  | Patients, N | Outcome                                                                 |
|-------------------|--------------------------------------|------------------------------------|-------------|-------------------------------------------------------------------------|
| Fiorentino et al24| Prospective observational study      | 375 mg/m², 4-weekly IV infusions   | 38          | 39.5% CR                                                                |
|                   |                                      |                                    |             | 36.8% PR                                                                |
|                   |                                      |                                    |             | 76.3% CR or PR                                                          |
|                   |                                      |                                    |             | Decreased proteinuria                                                  |
|                   |                                      |                                    |             | Increased albuminemia                                                   |
|                   |                                      |                                    |             | Decrease in circulating CD19⁺ B-cells                                   |
| Ruggenenti et al55| Prospective observational study      | 375 mg/m², 4 weekly IV infusions   | 8           | Decreased proteinuria                                                  |
|                   |                                      |                                    |             | Increased serum albumin concentration                                  |
|                   |                                      |                                    |             | Renal function stabilized                                              |
| Fernando et al56  | Prospective study                    | 375 mg/m², 4 weekly IV infusions   | 20          | Decreased proteinuria                                                  |
|                   |                                      |                                    |             | Increased creatinine clearance                                          |
|                   |                                      |                                    |             | CR in 4 patients                                                        |
|                   |                                      |                                    |             | PR in 12 patients                                                       |
| Busch et al57     | Prospective single center study      | 375 mg/m², 4 weekly IV infusions   | 14          | Decreased proteinuria                                                  |
|                   |                                      |                                    |             | CR in 3 patients                                                        |
|                   |                                      |                                    |             | PR in 12 patients                                                       |
| Ruggenenti et al58| Prospective observational study      | 375 mg/m², 4 weekly IV infusions   | 100         | 65 patients achieved CR or PR                                           |
|                   |                                      |                                    |             | Increased serum albumin concentration                                  |
|                   |                                      |                                    |             | Decreased proteinuria                                                  |
| Cravedi et al59   | Prospective, matched-cohort study    | 375 mg/m², 4 weekly IV infusions   | 11          | Decreased proteinuria                                                  |
|                   |                                      |                                    |             | 8 patients and 7 reference patients achieved full (3 vs 2) or partial (5 per cohort) proteinuria remission |

CR, complete remission; PR, partial remission.

at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). Overall, rituximab treatment was well tolerated.31

5  | FOCAL SEGMENTAL GLOMERULOSCLEROSIS

The treatment of idiopathic steroid-resistant FSGS remains a worrying challenge for nephrologists. The potential usefulness of rituximab has also been explored in patients with steroid-dependent or steroid-resistant forms of nephrotic syndrome.28 In a multicenter retrospective study by Garrouste et al, 19 patients who developed FSGS recurrence at 12 (1.5–27) days post transplantation were treated with rituximab (375 mg/m², a median of 2 (1-4) infusions). Nine of 19 had complete remissions and 3 of 19 had partial remissions. Estimated glomerular filtration rates were significantly higher in the responding patients than in nonresponding patients at month (M)12, M36, and M60. Kidney survival at 5 years was 77.4%. The 5-year graft survival rates in the responding patients and the nonresponding patients were 100% and 36.5%, respectively (P = 0.01).29 Fornoni et al treated 27 out of 41 patients with rituximab (375 mg/m², single dose) at high risk of recurrent FSGS at the time of kidney transplant. Their study suggested that treatment of high-risk patients with rituximab at the time of kidney transplant might prevent recurrent FSGS by modulating podocyte function in an SMPDL-3b-dependent manner.30

6  | ANTINEUTROPHIL CYTOPLASMIC ANTIBODY

Microscopic polyangiitis and Wegener’s granulomatosis are classified as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, as most patients with generalized disease have antibodies against proteinase 3 or myeloperoxidase. The ANCA-associated vasculitides affect small-to-medium-size blood vessels, with an inclination for the respiratory tract and kidneys. In ANCA-associated vasculitis, the percentage of activated peripheral-blood B lymphocytes correlates with disease activity. Studies suggest that rituximab has shown promise as a remission-induction agent in ANCA-associated vasculitis by depleting B-cells.31,32 In a multicenter, randomized, double-blind, double-dummy, noninferiority trial by Stone et al, rituximab therapy was found to be more effective than daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis. A total of 197 ANCA-positive patients were randomized to receive rituximab in cyclophosphamide. Primary end point was achieved by 64% of patients in the rituximab group compared to 53% of patients in cyclophosphamide group. The rituximab-based regimen was more efficacious than the cyclophosphamide-based regimen for inducing remission of relapsing disease (67% vs 42%). Rituximab was also as effective as cyclophosphamide in the treatment of patients with major renal disease or alveolar hemorrhage. No significant differences between the treatment groups with respect to rates of adverse events was observed.33
In a single-center cohort study by McAdoo et al of 66 patients with renal anti-neutrophil cytoplasm antibody-associated, a combined regimen of rituximab and cyclophosphamide proved to be potentially superior to current standards of care. Sixty-six patients were treated with a combination of oral corticosteroids, rituximab and low-dose pulsed intravenous cyclophosphamide, followed by a maintenance regimen of azathioprine and tapered steroid for the treatment of biopsy-proven renal involvement in AAV. Ninety-four per cent of patients achieved disease remission by 6 months. Patient and renal survival were 84% and 95%, respectively, at 5 years. Eighty-four per cent achieved ANCA-negative status and 57% remained B-cell depleted at 2 years, with low rates of major relapse. The serious infection rate during long-term follow-up was 1.24 per 10 patient-years. Treatment with this regimen was associated with a reduced risk of death, progression to end-stage renal disease, and relapse, compared with propensity-matched patients enrolled in EUVAS trials.

7 | HAEMOLYTIC URAEMIC SYNDROME

Thrombotic thrombocytopenic purpura (TTP) is a rare disorder characterized by thrombocytopenia, microangiopathic haemolytic anaemia, neurological and renal abnormalities and fever. Since such criteria do not distinguish TTP from haemolytic uraemic syndrome (HUS), the comprehensive term TTP-HUS is more appropriate. Rituximab is reportedly effective in TTP-HUS patients with or without antibody-mediated ADAMTS-13 deficiency, as well as in cases of refractory/relapsing cases. In 4 cases reported by Caramazza et al, patients with relapsed or refractory HUS received rituximab initiated as a single agent once a week for 4 weeks, at a dose of 375 mg/m². All four patients achieved clinical remission and rituximab was well tolerated. In Kameda et al reported two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease. After both patients received two doses of intravenous rituximab (375 mg/m² once per week), hemoglobin level and platelet counts were gradually elevated and fragmented red blood cells disappeared.

8 | RITUXIMAB IN RENAL TRANSPLANTATION

Rituximab is widely used in ABO blood group incompatible transplantation. It is also an effective treatment for post-transplant lymphoproliferative disorder, and is used in both human leukocyte antigen (HLA) antibody incompatible renal transplantation and the treatment of acute rejection. Historically, ABO-incompatible (ABOi) kidney transplantations have only been undertaken after splenectomy and unspecific plasmapheresis and with quadruple drug immunosuppression plus B-cell specific drugs. The first description of use of rituximab to replace splenectomy as a desensitization treatment in ABOI renal transplantation came from Stockholm in 2003. A protocol with a 10-day pre-transplant conditioning period, starting with single dose of rituximab (375 mg/m²), followed by full dose tacrolimus, mycophenolate mofetil, and prednisolone, followed by antigen-specific immunoadsorption, was used in four patients. The ABO-antibodies were readily removed by the antigen-specific immunoadsorption and were kept at a low level post transplantation by further adsorptions. There were no side effects, and all patients have normal renal-transplant function.

In another study by Tydén and colleagues, one dose of rituximab (375 mg/m²), was given 10 days prior to transplant to 12 patients, together with other immunsuppressants. Postoperatively, a standard triple-drug immunosuppressive protocol was followed, together with an immunosorbent. In the patient with the longest follow-up (almost 3 years), the CD20-positive cells were not detectable until 12 months posttransplantation. No side effects related to rituximab were observed and there were no serious infections. Recently Honda et al retrospectively compared 29 pediatric ABOI living donor liver transplantation (LDLT) recipients with 131 non-ABOI LDLT recipients. There were no significant differences in the incidence of infection, vascular complications, biliary complications, and acute cellular rejection between the ABOI and non-ABOI group. The cumulative graft survival rates at 1, 3, and 5 years for the non-ABOI group were 92.1%, 87.0%, and 86.1%, and those for ABOI group were 82.8%, 82.8%, and 78.2%, respectively. They concluded that ABOI LDLT is a feasible option for pediatric end-stage liver disease patients. The allograft survival and patient survival rates for published reports of ABOI renal transplantation using rituximab are summarized in Table 2.

In HLA antibody incompatible renal transplants, rituximab is often given at the time of transplantation or even post transplant. Jackson et al examined post-transplant HLA antibody levels in 25 recipients desensitized with rituximab induction and 25 without, to determine the impact of B-cell depletion. They found significantly less HLA antibody rebound in the rituximab-treated patients (7% of donor specific antibodies (DSAs) and 33% of non-DSAs) compared to a control cohort desensitized and transplanted without rituximab (32% DSAs and 55% non-DSAs). Also, the magnitude of the increase was significantly larger among patients who did not receive rituximab. Compared to controls, rituximab-treated patients had a significantly greater mean reduction in DSA (~2505 vs ~292 mean fluorescence intensity), but a similar rate of DSA persistence (52% in rituximab treated and 40% in nontreated recipients). They inferred that rituximab induction in HLA incompatible recipients reduced the incidence and magnitude of HLA antibody rebound, without affecting DSA elimination, or antibody mediated rejection. Use of rituximab as a treatment for acute renal allograft rejection has been purely descriptive, mainly single-case reports or case series. In a randomized controlled trial, Zarkhin et al reported 1-year outcomes of rituximab vs standard-of-care immunosuppression for treatment of biopsy confirmed, acute transplant rejection with B-cell infiltrates, in 20 consecutive recipients (2-23 years). Rituximab was administered by intravenous infusion at a standard dose of 375 mg/m² weekly for four consecutive weeks. Complete tissue B-cell depletion and rapid peripheral B-cell depletion was observed. Peripheral CD19 cells recovered at a mean time of approximately 12 months. Some benefits in recovery.
of graft function (P = 0.026) and improvement of biopsy rejection scores at both the 1- (P = 0.0003) and 6-month (P < 0.0001) follow-up biopsies were observed. Reappearance of C4d deposition was absent in follow-up biopsies after rituximab therapy, but was present in 30% of control patients. There was no change in DSA in either group, independent of rejection resolution.48

A few clinical studies have shown improvement in the treatment of chronic active antibody-mediated rejection (CAMR) following the administration of rituximab in combination with other therapies in some patients.49 Hong et al administered a single dose of rituximab (375 mg/m²) together with intravenous immunoglobulin (IVIg) in six renal transplant recipients who showed progressive deterioration in graft function and CAMR as diagnosed by biopsy. After the treatment, allograft function improved or stabilized in 3 patients in the responder group. The amount of proteinuria also decreased in the responder group, suggesting that the combination of rituximab and IVIg was effective in early-stage CAMR.50

The term PTLD encompasses a heterogeneous group of lymphoproliferative disorders that may occur after transplantation of solid organs and hematopoietic cells.51 PTLD has been reported in 1% of

| TABLE 2 | Results from adult ABOi renal transplant programs using rituximab |
| Authors | Number of patients | Dose of rituximab | Follow-up | Outcome |
| Sonnenday et al60 | 6 | 375 mg/m², single dose | 12 mo | Mean SCR. was 1.3 ± 0.1 mg/dL No episodes of AMR Stable allograft function |
| Genberg et al61 | 15 | 375 mg/m², single dose | 3 y | 100% patient survival 87% overall graft survival Acute rejection in 1 patient |
| Sivakumar et al62 | 10 | 375 mg/m², single dose | 1 y | 100% patient survival Mean SCR = 1.45 ± 1.04 mg/dL 4 episodes of AMR 2 incidents of DGF |
| Genberg et al63 | 43 | 375 mg/m², single dose | 4.5 y | 93% overall patient survival 91% graft survival 9.3% incidence of AMR |
| Melexopoulou et al64 | 30 | 375 mg/m², single dose | 6 y | 92% patient survival 81% graft survival No CAMR 13.3% ACR |
| Jha et al65 | 20 | 200 mg, single dose | | 90% patient survival 95% graft survival 15% AMR |
| Lee et al66 | 59 | 375 mg/m², or 200 mg single dose | 2 y | 95.8% patient survival 94.9% graft survival 15.3% AMR 1 graft loss |
| Kong et al67 | 79 | 53% patients mean 644 ± 226 mg/body47% patients 203 ± 14 mg/body | 21 mo | 99.2% patient survival 97.5% graft survival 14% patients had acute rejection |
| Rostaing et al68 | 12 | 375 mg/m², two dose | 19 mo | 91.6% graft survival 100% patient survival 3 patient had CAMR 58.3% showed nearly normal kidney biopsy |
| Ray et al69 | 45 | 200 mg/body single infusion | 370 d | Mean SCR = 1.21 mg% 97.78% graft survival 97.78% patient survival |

ACR, acute cellular rejection; AMR, antibody-mediated rejection; CAMR, chronic antibody-mediated rejection; DGF, delayed graft function; SCR, serum creatinine.
renal transplant recipients. Rituximab has been demonstrated to be an effective treatment for PTLD. In a retrospective study of eight patients with PTLD, Nieto-Rios et al concluded that the disorder can be managed successfully, with reduction of immunosuppression, conversion to m-TOR, and rituximab-based schemes. The first-line therapy consisted of rituximab given as a 375 mg/m² intravenous infusion for 4 hours, weekly. The overall response rate was 87.5% (62.5% complete response, 25% partial response). Survival was 87.5%, with a median follow-up of 34 months.

9 | CONCLUSION

Emerging evidence suggests that rituximab may be an effective and safe treatment in renal disorders and renal transplant. However, ideal dosing strategies and combination with other agents is still debatable. Studies designed to answer these questions should delineate the best use of rituximab in nephrology, and randomized controlled trials are clearly required before accepting rituximab as a standard treatment.

CONFLICT OF INTEREST

None.

ORCID

Kajal Chauhan https://orcid.org/0000-0002-7164-1767

REFERENCES

1. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
2. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2009;6:13-19.
3. Bryan J, Borthakur G. Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag. 2011;7:1-11.
4. FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris. June 7, 2018. https://www.gene.com/media/press-releases/14727/2018-06-07/fda-approves-genentechs-rituxan-rituxima. Accessed January 9, 2019.
5. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859-866.
6. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115-123.
7. Mohrbacher A, B cell non-Hodgkin’s lymphoma: rituximab safety experience. Arthritis Res Ther. 2005;7:S19-S25.
8. Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2:99-111.
9. Gunnarsson I, Jonsdottir T. Rituximab treatment in lupus nephritis—where do we stand? Lupus. 2013;22:381-389.
10. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol. 2009;4:724-744.
11. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-853.
12. Ayan G, Esatoglu SN, Hatemi G, et al. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatol Int. 2018;38:607-622.
13. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant. 2005;19:423-426.
14. Morath C, Zeier M, Döhler B, Opelz G, Süsal C. ABO-Incompatible kidney transplantation. Front Immunol. 2017;8:234.
15. Donadio JV Jr, Hart GM, Bergstrahl EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995;4:109-115.
16. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev. 2006;5:18-24.
17. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24:3717-3723.
18. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182.
19. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23:324-332.
20. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol. 2006;1:483-487.
21. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11-21.
22. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73:117-125.
23. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360:923-924.
24. Fiorentino M, Tondolo F, Bruno F, et al. Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J. 2016;9:788-793.
25. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol. 1991;19:621-624.
26. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008;111:1344-1356.
27. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepati- tis C virus and mixed cryoglobulinemia. Arthritis Rheum. 2011;64:835-842.
28. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220-2226.
29. Garrouste C, Canaud G, Büchner M, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: clinical outcomes. Transplantation. 2017;101:649-656.
30. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:38ra46.
31. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(643):e9-e14.
32. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43:1021-1032.
33. Stone JH, Merkel PA, Sipiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.
34. McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen
in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant. 2018;33:899.

35. Amorosi EL, Ullmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139-159.

36. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.

37. Fankouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13 deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932-1937.

38. Kameda T, Dobashi H, Kittaka K, et al. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol. 2007;26:2159-2162.

39. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol. 2005;84:232-235.

40. Caramazza D, Quintini G, Abbene I, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome. Blood Transfus. 2010;8:203-210.

41. Tydén G, Kumlien G, Wennberg L, Tydén G. Long-term results of ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003;76:730-731.

42. Tydén G, Kumlien G, Genberg H, Sandberg T, Lundgren T, Fehrmann I. Successful ABO-incompatible kidney transplantations without splenectomy using anti-A/B antigen-specific immunoadsorption and rituximab. Transplantation Proc. 2003;35:3744-3748.

43. Honda M, Sugawara Y, Kadohisa M, et al. Long-term outcomes of ABO-incompatible pediatric living donor liver transplantation. Transplantation. 2018;102:1702-1709.

44. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc. 2008;40:2218-2221.

45. Yin H, Hu XP, Li XB, et al. Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J (Engl). 2009;122:2752-2756.

46. Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA. A closer look at rituximab induction on HLA antibody rebound following HLA incompatible kidney transplantation. Kidney Int. 2015;87:409-416.

47. Bansal SB. Rituximab use in late antibody-mediated rejection. Indian J Nephrol. 2016;26:315-316.

48. Zarkhin V, Li L, Kambharn T, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant. 2008;8:2607-2617.

49. Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. Transplant Rev. 2017;31:87-95.

50. Hong YA, Kim HG, Choi SR, et al. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant Proc. 2012;44:182-184.

51. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12:383-394.

52. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:70-78.

53. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int. 2006;19:259-269.

54. Nieto-Rios JF, Gómez de los Ríos SM, Serna-Higuita LM, et al. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med. 2016;47:196-202.

55. Ruggenenti P, Churičiću C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14:1851-1857.

56. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010;5:2188-2198.

57. Busch M, Rüster C, Schinköthe C, Gerth J, Wolf G. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clin Nephrol. 2013;80:105-113.

58. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1416-1425.

59. Cravedi P, Sghirlanzoni MC, Marasà M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011;33:461-468.

60. Sonndenay CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant. 2004;4:1315-1322.

61. Genberg H, Kumlien G, Wennberg L, Tydén G. Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoabsorption and rituximab. Transplantation. 2007;84:544-547.

62. Sivakumaran P, Vo AA, Villicana R, et al. Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. J Clin Apher. 2009;24:155-160.

63. Genberg H, Kumlien G, Wennberg L, Tydén G. The efficacy of antigen-specific immunoabsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2011;26:2394-2400.

64. Melexopouolou C, Marinaki S, Liapis G, et al. Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: experience of one center. World J Transplant. 2015;5:329-337.

65. Jha PK, Bansal SB, Sethi SK, et al. ABO-incompatible renal transplantation in developing world – crossing the immunological (and mental) barrier. Indian J Nephrol. 2016;26:113-118.

66. Lee KW, Park JB, Oh DK, et al. Short-term outcomes of ABO-incompatible living donor kidney transplantation with uniform protocol: significance of baseline anti-ABO titer. Transplant Proc. 2016;48:820-826.

67. Kong JM, Ahn J, Park JB, et al. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome. Clin Transplant. 2013;27:875-881.

68. Rostaing L, Karam B, Congy-Jolivet N, et al. Successful transplantation in ABO- and HLA-incompatible living kidney transplant patients: a report on 12 cases. Ther Apher Dial. 2016;20:507-516.

69. Ray DS, Thukral S. Outcome of ABO-incompatible living donor renal transplantations: a single-center experience from eastern India. Transplant Proc. 2016;48:2622-2628.

How to cite this article: Chauhan K, Mehta AA. Rituximab in kidney disease and transplant. Animal Model Exp Med. 2019;2:76-82. https://doi.org/10.1002/ame2.12064